NCT02893423

Brief Summary

With this research the investigators hope to determine the lowest dose of ropivacaine used in transversus abdominis plane (TAP) blocks that can effectively treat pain in women after cesarean section (c-section).

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
51

participants targeted

Target at below P25 for not_applicable postoperative-pain

Timeline
Completed

Started Jan 2013

Longer than P75 for not_applicable postoperative-pain

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2013

Completed
3.5 years until next milestone

First Submitted

Initial submission to the registry

June 26, 2016

Completed
2 months until next milestone

First Posted

Study publicly available on registry

September 8, 2016

Completed
22 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2016

Completed
6 years until next milestone

Results Posted

Study results publicly available

September 21, 2022

Completed
Last Updated

September 21, 2022

Status Verified

May 1, 2022

Enrollment Period

3.7 years

First QC Date

June 26, 2016

Results QC Date

May 16, 2022

Last Update Submit

August 27, 2022

Conditions

Keywords

RopivacaineC-Section AnalgesiaTap Block

Outcome Measures

Primary Outcomes (1)

  • POSTOPERATIVE PAIN

    Severity of postoperative pain will be assessed using(VAS) scale. Post-operative pain scale name: Visual Analog Scale (0-10) with 0 being no-pain and 10 being maximum pain.

    48 hours

Study Arms (3)

Group 1 - 0.5% Ropivacaine

ACTIVE COMPARATOR

Patients will receive 0.5% Ropivacaine for the TAP block Procedure: Ultrasound guided TAP BLOCK Drug: 0.5% ropivacaine 20ml of 0.5% ropivacaine is used to perform the TAP block Other Names: •Naropin

Drug: Ropivacaine

Group 2 - 0.25% Ropivacaine

ACTIVE COMPARATOR

Patients will receive 0.25% for the TAP block Procedure: ULTRASOUND GUIDED TAP BLOCK Drug: 0.25% ropivacaine 20ml of 0.25% ropivacaine is used to perform the TAP block Other Names: •Naropin

Drug: Ropivacaine

Group 3 - No Tap Block

NO INTERVENTION

Patients will not receive a TAP BLOCK

Interventions

Using 2 Different Concentrations of Ropivacaine in Tap Block for Postoperative Analgesia for C-Section Patients

Also known as: Naropin
Group 1 - 0.5% RopivacaineGroup 2 - 0.25% Ropivacaine

Eligibility Criteria

Sexfemale
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Pregnant patients undergoing elective c-section

You may not qualify if:

  • Allergy to local anesthetics
  • Contraindication to tap blocks

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Maimonides Medical Center

Brooklyn, New York, 11219, United States

Location

MeSH Terms

Conditions

Pain, Postoperative

Interventions

Ropivacaine

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Intervention Hierarchy (Ancestors)

AnilidesAmidesOrganic ChemicalsAniline CompoundsAmines

Results Point of Contact

Title
Kalpana Tyagaraj
Organization
Maimonides Medical Center

Study Officials

  • KALPANA TYAGARAJ, MD

    MAIMONIDES MEDICAL CENTER, 4802, 10TH AVENUE, BROOKLYN, NY-11219

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Residency Program Director

Study Record Dates

First Submitted

June 26, 2016

First Posted

September 8, 2016

Study Start

January 1, 2013

Primary Completion

September 30, 2016

Study Completion

September 30, 2016

Last Updated

September 21, 2022

Results First Posted

September 21, 2022

Record last verified: 2022-05

Data Sharing

IPD Sharing
Will not share

Locations